pharmaphorum

JANUARY 11, 2022

A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device status by the FDA. The post Blue Note leukaemia DTx gets FDA breakthrough tag appeared first on. Other DTxs are aimed at people being treated for breast and lung cancers.

Development 62

Development Production Drugs 62

Pharmaceutical Technology

MAY 2, 2023

In contrast to ICIs, which are utilised against solid tumours, cell therapies and bispecifics have been transformational in the haematological cancer settings, with approvals across a range of leukaemias and lymphomas. Cost-related unmet needs also scored highly.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

Drug Discovery World

MARCH 2, 2023

New understanding of epigenetics It has been known for more than 20 years that the enzymes placing H3K4me3, a chemical tag added to DNA, are crucial for normal cell development, as well as being linked to leukaemia, breast, bowel and pancreatic cancers.

Gene Expression 52

Gene Expression Gene DNA RNA 52

pharmaphorum

APRIL 20, 2021

NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year. Novartis took ownership of the drug in 2015.

Sales 109

Sales Medicine Drugs Marketing 109

pharmaphorum

FEBRUARY 22, 2021

Last week, Bluebird said it was pausing its Zynteglo (betibeglogene autotemcel) programme in Europe after a phase 1/2 trial in patients with sickle cell disease (SCD) – another red blood cell disorder – turned up two cases of blood cancers, one of acute myeloid leukaemia (AML) and another of myelodysplastic syndrome (MDS). million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

Drug Discovery World

MAY 22, 2023

But are these price tags a barrier to access? Patient access A study on the socioeconomic backgrounds of CAR-T patients showed that children from across the spectrum of treatment for acute lymphoblastic leukaemia received similar results. million per dose.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

pharmaphorum

DECEMBER 2, 2020

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche. The New York-based firm has requested approval for the combination of its anti-CD20 antibody ublituximab and umralisib, an oral drug that inhibits PI3K-delta and CK-1 epsilon.

Drugs 52

Drugs Trials Antibody Marketing 52